Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dietary and Topical Magnesium Replacement in Lymphoma Patients
NCT05294367Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Apr 2022
- Primary completion
- Apr 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of magnesium chloride in hypomagnesemia (3 arms), sponsored by Mayo Clinic. Primary endpoint: Improvement in serum magnesium levels at 56 days. Started Apr 2022; status: recruiting.
02
Drugs
magnesium chloride
03
Conditions
hypomagnesemia
Beyond the preview
Go deeper on NCT05294367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05294367.